Drug Type Antibody fusion proteins |
Synonyms IMC-002, IMM 0306 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuromyelitis Optica | Phase 2 | - | 10 Oct 2024 | |
Systemic Lupus Erythematosus | Phase 2 | CN | 12 Aug 2024 | |
Follicular Lymphoma | Phase 2 | CN | 07 Jun 2023 | |
Mantle-Cell Lymphoma | Phase 2 | CN | 07 Jun 2023 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | - | 01 May 2023 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | - | 01 May 2023 | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 2 | CN | 02 Mar 2020 | |
B-Cell Lymphoma | Phase 1 | US | 15 Jan 2021 | |
Lupus Nephritis | IND Approval | CN | 29 Nov 2024 |
NCT05805943 (ASH2024) Manual | Phase 1 | 48 | pxyulsgjew(kbgmscjgha) = opzfhldaxr inilnaonoe (omkagstmwq ) View more | Positive | 07 Dec 2024 | ||
(r/r follicular lymphoma (FL)) | pxyulsgjew(kbgmscjgha) = roopmgvsop inilnaonoe (omkagstmwq ) View more | ||||||
NCT05805943 (ESMO2024) Manual | Phase 2 | CD20 Positive B-Cell Non-Hodgkin Lymphoma CD20 Positive | 16 | Amulirafusp alfa (IMM0306) 2.0 mg/kg | (nzyhkpvnih) = oiauvfvfki dqistdjdga (fnvkhpuzej ) View more | Positive | 15 Sep 2024 |
Phase 1 | 48 | vsefirgwxa(pwgeudrycy) = wlwzzuvble hgrdbfpmvk (wcgglgfyot ) View more | Positive | 24 May 2024 | |||
vsefirgwxa(pwgeudrycy) = sspsvyncua hgrdbfpmvk (wcgglgfyot ) View more | |||||||
NCT05805943 (AACR2024) Manual | Phase 1 | 48 | jfylzdxfpo(dsrhdvxbsg) = The most frequent treatment related adverse events (TRAEs) were WBC decreased (66.7%), anemia (64.6%), lymphocyte decreased (58.3%), ANC decreased (47.9%), PLT decreased (45.8%), infusion-related reactions (35.4%) wqawnpdsfl (cziflkhqll ) View more | Positive | 05 Apr 2024 | ||
CTR20192612 (ASCO2023) Manual | Phase 1/2 | CD20 Positive B-Cell Non-Hodgkin Lymphoma CD20 Expression | 42 | klxgwvcpvc(tjoqhadafg) = Three treatment related SAEs were PLT decreased (grade 4), chest pain (grade 2) and diarrhea (grade 3). ktkbmvtezw (tjmfppyvxr ) View more | Positive | 31 May 2023 |